Rape. James Comer, R-K.
Regenron Pharmaceuticals announced on Monday that it would acquire “adequate all” of the genetic testing company 23andme’s assets.
The pharmaceutical company stated that it won the genetic testing company’s court-served auction, in which Rejoron agreed to pay $ 256 million for the property. 23andme said as part of the auction Chapter 11 bankruptcy Protection This was filed in March to facilitate the sale of its business.
In its bankruptcy petition, the company estimated a range of $ 100 million to $ 500 million for its assets. Estimated liabilities were the same.
Genetics Testing Company 23andme filed chapter 11 for insolvency conservation in March. (Justin Sulivan / Getty Image / Getty Images)
Regenron said deal The 23andme assets will be closed in the third quarter of 2025, provided that it will receive approval from the bankruptcy court while observing the case of chapter 11 bankruptcy of the genetic testing company. The deal will be weighed by the court in mid -June.
23andMe files for bankruptcy as California AG urge customers to remove data
According to 23andme, the pharmaceutical company is purchasing 23And individual genome service and its total health and research service segments.
The 23andme stated that the deal includes Regenron’s commitment to compliance with the company’s confidentiality policies and applied laws, all customers processing personal data, processing in accordance with the terms of consent, privacy policies, and statements, service, and the safety control currently designed to protect such data is currently safety control. ,
| Langer | Security | Last | Change | Change % |
|---|---|---|---|---|
| Registration | Regeneron pharmaceuticals inc. | 588.34 | -8.51 |
-1.43% |
“Through our Regoron Genetics Center, we have a proven track record of protecting individual genetic data, and we assure 23nd customers that we will implement our high standards for their data and safety and integrity for consumer genetic services,” George Yankopolos, Regoron’s board said in a statement.
Regenronon said that the deal to buy a 23andme assets would be closed in the third quarter of 2025. ,
“We believe that we can help 23andme to distribute and construct our missions to know about our own DNA and to help improve their personal health, while improving the efforts to improve Reengaron’s efforts. Health and welfare Of many, “he said.
23andme bankruptcy: Will your personal data be protected?
A court appointed by a court will provide secrecy Lokpal Court The 23andme’s proposed purchase of 23andme and the impact, “If any, on the privacy of consumers, said,” 23andme said, “with a report on 10 June,” 23andme said.
Regeneron wants to create a “full ownership or assistant” assistant 23andme of the company after procurement, with a plan to maintain its individual genomics service.
23andme stated that the consumer secrecy Lokpal appointed by a court on June 10, the proposed procurement of 23andme and “impact, if any, on the privacy of consumers, said,” 23andme said, “said a report on 10 June,” 23andme said. (Smith Collection/Gado/Getty Image/Getty Images)
Mark Jensen of 23andme said, “We are pleased to reach a transaction that maximizes the business value and enables the mission of 23andme to remain, while the customer said, while maintaining significant security about privacy, choice and consent, in relation to his genetic data,” said Mark Jensen of 23andme.
23andme 2023 Data agrees to pay $ 30M to prosecute breech
23andme also ran Telehealth Assistant Lamad Health. The business that Rejoron is not buying will be closed.
